Viridian Shares Fall 34 Percent on Eye Drug Trial Results
Viridian shares fell on Monday after its thyroid eye disease drug trial results trailed expectations. The firm plans a marketing application for early 2027.
Xurve View
Insights:
Xurve View
Shares of Viridian Therapeutics, Inc. plummeted 34% to an eight-month low on Monday after the company released late-stage clinical data for its experimental thyroid eye disease treatment. While the drug, elegrobart, met its primary goals in reducing eye bulging, the level of efficacy fell short of investor expectations and lagged behind competing therapies already on the market.
